Clinical Trials in Grenoble, France
2 recruiting
Showing 1–20 of 40 trials
Recruiting
Phase 1Phase 2
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NSCLC
Regeneron Pharmaceuticals231 enrolled40 locationsNCT04077099
Recruiting
Phase 2
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Pleural Mesotheliomas
Intergroupe Francophone de Cancerologie Thoracique38 enrolled20 locationsNCT06840834
Recruiting
Phase 3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Neoplasms, Lung
GlaxoSmithKline420 enrolled102 locationsNCT07099898
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Metastatic CancerAdvanced CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc.200 enrolled120 locationsNCT05853575
Recruiting
Not Applicable
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
CancerThrombosisPulmonary Embolism
Centre Hospitalier Universitaire de Saint Etienne212 enrolled4 locationsNCT06386107
Recruiting
Phase 2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals120 enrolled49 locationsNCT06465329
Recruiting
Phase 3
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique129 enrolled40 locationsNCT06937905
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
REBECCA Real-world Early BrEast CanCer mAnagement
Breast Cancer
AstraZeneca126 enrolled44 locationsNCT06856343
Recruiting
Phase 2
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Hospices Civils de Lyon58 enrolled16 locationsNCT06866938
Recruiting
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
Prostate Cancer Metastatic Disease
University Hospital, Grenoble130 enrolled1 locationNCT06828263
Recruiting
Phase 3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique133 enrolled29 locationsNCT06908993
Recruiting
Not Applicable
Impact of a Physical Activity Intervention With Motivational Support From Peers for Prostate Cancer Patients
Prostate Cancer
Centre Hospitalier Universitaire de Saint Etienne850 enrolled25 locationsNCT05739565
Recruiting
Phase 1Phase 2
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Breast Cancer
Novartis Pharmaceuticals58 enrolled32 locationsNCT06247995
Recruiting
PRostate Olaparib Real World Evidence Study
Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Not Applicable
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer
Breast CancerCognitive Dysfunction
Centre Francois Baclesse300 enrolled25 locationsNCT06027632
Recruiting
Phase 3
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC1,600 enrolled9 locationsNCT05974774
Recruiting
Not Applicable
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Metastatic Triple-Negative Breast Carcinoma
UNICANCER472 enrolled51 locationsNCT06505018